Sánchez-Gundín Julia, Fernández-Carballido Ana María, Torres-Suárez Ana Isabel, Barreda-Hernández Dolores
Servicio de Farmacia, Hospital Virgen de la Luz, Cuenca. Departamento de Farmacia y Tecnología Alimentaria, Universidad Complutense de Madrid, Madrid.
Departamento de Farmacia y Tecnología Alimentaria, Universidad Complutense de Madrid, Madrid, nstituto de Farmacia Industrial, Universidad Complutense de Madrid, Madrid..
Farm Hosp. 2019 Mar 1;43(2):56-60. doi: 10.7399/fh.11156.
To evaluate and to compare quality of life of patients with non- metastasic colorectal cancer treated either with FOLFOX or with XELOX scheme.
Descriptive prospective study during 24 months (October 2015- October 2017) for patients with non-metastasic colorectal cancer in chemotherapy adyuvant treatment. EORTC QLQ-C30 questionnaire was filled by patients at the beginning and at week 12 of adjuvant treatment. Variables collected: exposure (chemotherapeutic scheme administered), control (demographic data, disease data, treatment data) and response (scores obtained from the questionnaire). The data statistical analysis was carried out with the SPSS® 15.0 programme.
30 patients were included. Statistically significant differences were found in emotional role item at the middle of the treatment (FOLFOX 92 points vs. XELOX 82 points; p = 0,036). Patients with FOLFOX presented a clinically relevant worsening in terms of daily activities, constipation and insomnia. Patients treated with XELOX a clinically relevant worsening in daily activities, constipation, fatigue, nausea, vomiting, anorexia and diarrhoea were observed.
Patients with XELOX scheme referred to have worse emotionally status in the middle of the adjuvant treatment than patients treated with FOLFOX scheme and presented a worsening in items fatigue, nausea, vomiting, anorexia and diarrhoea.
评估并比较接受FOLFOX或XELOX方案治疗的非转移性结直肠癌患者的生活质量。
对非转移性结直肠癌患者进行为期24个月（2015年10月至2017年10月）的描述性前瞻性研究，这些患者处于化疗辅助治疗阶段。在辅助治疗开始时和第12周，患者填写欧洲癌症研究与治疗组织生活质量核心问卷（EORTC QLQ-C30）。收集的变量包括：暴露因素（所给予的化疗方案）、对照因素（人口统计学数据、疾病数据、治疗数据）和反应因素（从问卷中获得的分数）。使用SPSS® 15.0程序进行数据统计分析。
纳入30例患者。在治疗中期，情绪角色项目存在统计学显著差异（FOLFOX方案为92分，XELOX方案为82分；p = 0.036）。接受FOLFOX方案治疗的患者在日常活动、便秘和失眠方面出现了具有临床意义的恶化。接受XELOX方案治疗的患者在日常活动、便秘、疲劳、恶心、呕吐、厌食和腹泻方面出现了具有临床意义的恶化。
接受XELOX方案治疗的患者在辅助治疗中期的情绪状态比接受FOLFOX方案治疗的患者差，并且在疲劳、恶心、呕吐、厌食和腹泻项目上出现了恶化。
